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Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate,
which acts as an oncometabolite. Germline SDHx mutations predispose to para-
ganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and
gastro-intestinal stromal tumors. The SDHx genes were the first tumor suppressor
genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto
Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dys-
function and cancer. Accumulation of succinate is the hallmark of tumorigenesis in
PGL and PCC. Succinate accumulation inhibits several α-ketoglutarate dioxygenases,
thereby inducing the pseudohypoxia pathway and causing epigenetic changes. More-
over, SDH loss as a consequence of SDHx mutations can lead to reprogramming of
cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and
other metabolites can be measured in tumor tissue, plasma and urine with different
techniques. Furthermore, these pathophysiological characteristics provide insight
into therapeutic targets for metastatic disease. This review provides an overview of
the pathophysiology and clinical implications of oncometabolite succinate in SDHx
mutations.
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1 | INTRODUCTION
Mutations of genes encoding for the succinate dehydrogenase (SDH)
complex, associated with familial paraganglioma (PGL) and pheochro-
mocytoma (PCC), lead to accumulation of succinate, which disturbs
the metabolic regulation of the cell. Nowadays metabolic dys-
regulation is recognized as one of the eight hallmarks of cancer.1
Although germline mutations in SDHx genes are predominantly
linked to PGL and PCC, these mutations also predispose to renal cell
carcinoma (RCC), gastrointestinal stromal tumors (GISTs) and,
possibly, pituitary adenomas. PCC, PGL and head and neck PGL
(HNPGL) are rare neuroendocrine tumors arising from chromaffin
cells that can synthesize and release catecholamines. Sympathetic
PGLs are derived from sympathetic paraganglia in the chest, abdo-
men or pelvis. PCC are PGLs located in the adrenal medulla.2
HNPGLs are derived from parasympathetic paraganglia. Common
locations for HNPGLs include the carotid body and the middle ear,
as well as the vagus nerve and internal jugular vein. While parasym-
pathetic PGLs are most often non-functional tumors, PCC and sym-
pathetic PGL release catecholamines into the circulation and can
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lead to severe (lethal) cardiovascular and cerebrovascular complica-
tions. Approximately, 40% of these tumors carry a germline muta-
tion in one of more than 20 susceptibility genes, of which the SDHx
genes are the most prevalent.3
In terms of genomic features, tumors related to SDHx mutations
are classified as cluster I, along with Von Hippel Lindau (VHL), fuma-
rate hydratase (FH), malate dehydrogenase 2 (MDH2), hypoxia induced
factor (HIF2α) and isocitrate dehydrogenase (IDH)-mutations and the
recently identified SLC25A11.4 Cluster I germline mutations predis-
pose to tumors characterized by a pseudohypoxic signature, in con-
trast to cluster II germline mutations, which are associated with
abnormal kinase signaling pathways and include mutations in the
genes of rearranged during transfection (RET), neurofibromatosis
(NF1), transmembrane protein 127 (TMEM127), kinesin family member
1B (KIF1B), and MYC-associated factor X (MAX). Cluster III is associ-
ated with the Wnt-signaling pathway; it includes somatic mutations of
cold shock domain-containing E1 (CSDE1) and mastermind-like tran-
scriptional coactivator 3 (MAML3) fusion genes.5,6
SDHx genes were the first to be recognized as tumor suppressor
genes encoding a mitochondrial enzyme. This resulted in an upsurge
of interest in the concept of aerobic glycolysis or the “Warburg
effect,” reported by Otto Warburg in 1926, which is characterized by
high glucose consumption and lactate production of cancer cells, even
in the presence of oxygen.7 This metabolic dysregulation is in fact rec-
ognized as one of the eight hallmarks of cancer.
Defective SDH function triggers the accumulation of succinate, an
intermediate metabolite of the tricarboxylic acid (TCA) cycle, which
plays a crucial role in the generation of adenosine triphosphate (ATP) in
mitochondria. Accumulation of succinate, along with other intermediate
metabolites of the TCA cycle, can give rise to the development and pro-
gression of cancer. FH mutations lead to the accumulation of fumarate,
and IDH mutations result in an accumulation of (R)-2-hydroxyglutarate.
These oncometabolites modulate the activity of α-ketoglutarate-
dependent dioxygenases, which are involved in the induction of the
pseudohypoxia pathway and inhibit histones and DNA demethylases,
resulting in a hypermethylator phenotype (also known as CpG island
methylator phenotype [CIMP]). The SLC25A11 gene encodes for a
mitochondrial carrier protein that is part of the malate-asparate shuttle
(this shuttle regenerates NADH to allow complex I to function), mediat-
ing the transport of α-ketoglutarate from the mitochondrial matrix to
the cytoplasm in exchange with malate. Preliminary results show that in
SLC25A11-mutated cells aspartate and glutamate concentration is
increased inducing the pseudohypoxic pathway and hypermethylation.4
Recognition of these pathophysiological characteristics provides
unique opportunities for diagnostic and therapeutic strategies. Over
the past years, several excellent reviews, such as those by Kucklova
et al, Morin et al and Vicha et al, have discussed the pathophysiology
of SDHx-related tumors.8-10 In the current review, we first present a
short summary of the SDH protein and the clinical features of SDHx-
mutation carriers. We then focus on the oncometabolite succinate
and its pivotal role in tumorigenesis in SDHx-related tumors, as well as
on the implications for clinical practice, especially diagnostics and
therapeutic options related to metastatic disease.
2 | SUCCINATE DEHYDROGENASE
SDH is a hetero-tetrameric mitochondrial enzyme that plays a role in
the TCA cycle and in the mitochondrial electron transport chain as
complex II (Figure 1). SDH catalyzes the oxidation of succinate to
fumarate in the TCA cycle and transfers electrons to the ubiquinone
(coenzyme Q) pool in the respiratory chain. SDH subunit A (SDHA)
and subunit B (SDHB) comprise the catalytic subunits in the hydro-
philic head that protrudes into the mitochondrial matrix. SDH subunit
C (SDHC) and subunit D (SDHD) are the ubiquinone-binding and
membrane-anchoring subunits. SDH assembly factor (SDHAF) is
required for the flavination of SDHA, which is essential for the forma-
tion of the SDH complex. The SDHA gene is located on chromosome
5p15.33 and contains 16 exons.11 SDHA is the major catalytic sub-
unit, converting succinate to fumarate. It contains the binding site for
succinate. The gene encoding for SDHB is located on chromosome
1p35-36.1 and has eight exons12; the SDHB protein contains three
Fe-S centers and mediates electron transfer to the ubiquinone pool.
The gene encoding SDHC is located at 1q21 and has six exons,13 and
the SDHD gene is located on chromosome 11q23 and has four
exons.14 SDHC and SDHD bind ubiquinone, generating protons even-
tually leading to the production of ATP.
3 | PHENOTYPE OF SDHX MUTATION
CARRIERS
Although different SDHx mutations occur in genes encoding for a sin-
gle enzyme, the clinical picture for each subunit differs with regard to
penetrance, manifestations and rate of malignancy. International
guidelines advice to screen all germline mutation carriers, however
with different screenings strategies for different SDHx mutation car-
riers.15 Screenings advices do not only differ between the different
mutations, but also over time, because studies on penetrance differ
over time regarding the population studied (index included or not), the
imaging methods used and the duration of follow-up. Adherence to
screening, leads to the detection of smaller PCC/PGL and might even
lead to an improved survival for patients who develop metastases,
although this is based on only few patients.16
Until now, a clear explanation for the difference of the clinical
picture between different SDHx mutations is lacking, except for the
hypothesis that the extent of SDH deficiency or loss depends on the
subunit. Apart from the differences, all SDHx mutations are charac-
terized by the (potential) presence of PGL/PCC. SDHx-associated
tumors harbor germline and somatic mutations, consistent with
Knudson's second-hit hypothesis.12 This hypothesis states that the
combination of an inactivating germline mutation as a first hit, and
somatic loss of function of the wild type allele as a second hit, is
essential for tumor development.17 This second hit usually is an
inactivation of the normal allele, that is, loss of 1p as was shown in a
large genomic study.18
Germline SDHx mutations have been associated with neoplasms
other than PGL/ PCC, such as RCC,19-21 GISTs and possibly pituitary
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adenoma.22-24 In addition, somatic SDHx mutations have been
described in T-cell leukemia.25 Because the discovery of SDHx genes
is relatively recent, the full clinical phenotype of these carriers remains
to be sufficiently clarified. The following paragraphs describe the cur-
rently known phenotype of each SDHx subunit (Table 1). The question
of why SDHx mutations predispose to tumors in a select subset of tis-
sues remains elusive.
3.1 | SDHA mutations
Mutations in the SDHA gene were originally described as a cause of
autosomal recessive juvenile encephalopathy, also known as Leigh
syndrome.26 Later on, in 2010, a 32 year old woman with an abdomi-
nal PGL was reported to have a heterozygous SDHA germline muta-
tion.27 Mutations in the SDHA gene remain a rare cause of PGL and
F IGURE 1 Succinate dehydrogenase (SDH) complex (simplified). The catalytic subunits SDH subunit A contains the flavin cofactor (FAD)
which accepts electrons from succinate and passes them to Fe-S center in the SDH subunit B subunit. The electrons are then passed the
ubiquinone pool embedded in SDHC and SDHD subunits. Reduced Q (QH2 = ubiquinol) transfers electrons within the mitochondrial inner
membrane space to complex III
TABLE 1 Phenotypic features of SDHx mutation carriers
Prevalence (%) Penetrance Mode of inheritance PCC sPGL HNPGL Multifocality Metastasis Other tumors
SDHA 1–7 Low AD + + ++ Rare Yes GIST, PA, NB
SDHB 8–10 Medium AD + ++ + Rare Frequent GIST, RCC, PA
SDHC 1–2 Low AD + + ++ Frequent Rare GIST, RCC, PA
SDHD 5–9 High Paternal transmissiona + + ++ Frequent Rare GIST, PA, RCC
SDHAF2 <1 Unknown Paternal transmissiona − − ++ Frequent Unknown PA
Abbreviations: AD, autosomal dominant; GIST, gastrointestinal stromal tumor; HNPGL, head and neck paraganglioma; NB, neuroblastoma; PA, pituitary
adenoma; PCC, pheochromocytoma; RCC, renal cell carcinoma; SDH, succinate dehydrogenase; SDHAF2, SDH assembly factor; SDHA, SDH subunit A;
SDHB, SDH subunit B; SDHC, SDH subunit C; SDHD, SDH subunit D; sPGL, sympathetic paraganglioma; −, manifestation (to our knowledge) not
described in these mutation carriers.+, manifestation present in these mutation carriers; ++, most common manifestation of these mutation carriers.
aSDHD and SDHAF2 autosomal dominant with maternal imprinting.
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account for 1% to 7% of all PGL cases.28,29 About half of SDHA muta-
tion carriers present with HNPGL, although sympathetic PGL and
PCC are also reported.30-32 Recently, van der Tuin et al calculated the
penetrance of SDHA mutation in a cohort comprising 86 patients
(30 index and 56 non-index patients). The penetrance for all manifes-
tations was only 10% at age 70 in non-index patients, but 50% at age
70 when both index and non-index patients were included in the
analysis.32
Metastatic disease was reported in 0% to 33% of PGL patients
with SDHA mutations, although these reports included few patients
(n = 4-34).31-36 GISTs and pituitary adenomas were reported in a small
subset of patients.24,31,32,37,38 In a large pediatric GIST study of
Boikos et al, a SDHA mutation, germline or somatic, was the most
common molecular subtype39 Neuroblastoma was reported in one
SDHA mutation carrier where it was possible to confirm loss of het-
erozygosity (LoH) in tumor tissue.38
3.2 | SDHB mutations
Mutations in the SDHB gene are those most frequently found in PGL
and account for about 10% of all cases of PGL.28 Most common mani-
festations are sympathetic PGLs (50%), whereas PCC and HNPGL
occur less often (20%-25% and 20%-30%, respectively).15 Bilateral
PCCs appear to be rare in SDHB mutation carriers. Penetrance of dif-
ferent manifestations decreases over time as more asymptomatic car-
riers are identified. Earlier studies of penetrance included mostly
index patients, thereby overestimating the penetrance. A recent study
by Andrews et al calculated the cumulative tumor risk in a large cohort
of 673 SDHB- mutation carriers and corrected for such ascertainment
bias by calculating not only the penetrance for only index patients,
but also for a combination of index and non-index patients.40 Their
Kaplan-Meier analysis showed an estimated risk for the combined
manifestation of PCC, sympathetic PGL and HNPGL in non-index
patients to be 22% at age 60.40 In their retrospective cohort analysis
(index and non-index patients) the penetrance was 24% at age
60 years.40 Males seem to be slightly more at risk than females of
developing a PGL.40,41
SDHB-related PGL/PCC are associated with a high risk of metasta-
sis and poor prognosis. Earlier studies report a higher metastatic rate
(31%-97%)42-45 than more recent studies.40 In a meta-analysis includ-
ing 12 studies comprising both asymptomatic SDHB carriers and car-
riers with manifest non-metastatic disease, van Hulsteijn et al
reported a metastatic rate of 17%.46 The risk of metastasis in HNPGL
in SDHB mutation carriers appears to be lower compared to PGL
developing at other sites.15 In a recent meta-analysis of the outcomes
of metastatic PGL and PCC, Hamidi et al found that the overall mor-
tality in SDHB mutation carriers ranged from 35% to 55% (n = 96)
compared to an overall mortality of 53% (95% confidence interval
43%-63%) in the whole group of PGL/PCC.47 In the past, several
studies have shown an association between SDHB-related metastatic
PGL/PCC and a shorter survival in patients compared to sporadic
metastatic PGL/PCC.48,49 In a recent analysis of Hescot et al, not the
SDHB mutation status but hypersecretion of metanephrines and
chromogranin A was found to be a significant prognostic factor for
worst overall survival.50
Other SDHB-associated tumors include RCC, although the risk
for this manifestation seems low, varying between 4.7% and
8%.21,40 GISTs are reported to occur in approximately 2% of SDHB
carriers.51 Pituitary adenoma have been reported in nine cases, but
only three had proven LoH (loss of heterozygosity) and abnormal
SDHB expression, thus confirming involvement of SDHB muta-
tion.24 Tufton et al reported a case of a SDHB mutation carrier with
pituitary carcinoma.52
3.3 | SDHC mutations
Mutations in the SDHC gene account for 1% to 2% of PGL/PCC
cases.28 SDHC typically manifest as benign, non-functional HNPGL,
although sympathetic PGL and PCC are also reported.53,54 Multiple
HNPGL are common.54 Penetrance for all PGL/PCC manifestations in
a cohort of 43 non-index SDHC carriers was 25% at age 60.40
Although metastatic disease seems to be rare in SDHC mutation
carriers, it has in a few cases been reported.40,55-57 Eight RCC and
multiple GISTs have been reported in SDHC carriers.19,58,59 Two cases
of pituitary adenoma have been described, although for LoH studies
no tissue was available to prove pathogenicity.24
3.4 | SDHD mutations
A mutation in the SDHD gene accounts for approximately 5% to 9%
of all cases of PGL/PCC.28,29 This gene follows an autosomal domi-
nant inheritance, modified by maternal imprinting. The predominant
clinical feature of SDHD carriers is the development of (multiple)
HNPGLs, as 85% of carriers develop tumors at this site.51 PCC and
sympathetic PGL occur less frequently in 10% to 25% and 20% to
25% of carriers, respectively. Penetrance for 160 non-index SDHD
mutation carriers was 43% at age 60.40
Metastatic risk in SDHD carriers is low and occurs in 7% to 8% of
cases.15,60 Other associated tumors include RCC and GIST, although
the lifetime risk for this manifestation is very low (<1%).40,61,62 Pitui-
tary adenomas are reported in five SDHD mutation carriers; in two of
these, both macroprolactinomas, the presence of LoH was
proven.22,23
3.5 | SDHAF2 mutations
The SDHAF2 gene, like SDHD, is affected by maternal imprinting;
therefore, only those carriers who inherit the mutation via the pater-
nal line will develop the disease. Only a few cases of PGL/PCC associ-
ated with SDHAF2 mutations have been described, and these account
for <1% of all cases of PGL.29 Germline pathogenic variants in
SDHAF2 have been seen only in association with HNPGLs.31,63-67
Kunst et al describe a large family of 16 patients, 11 with a HNPGL,
primarily at carotid body and vagal locations. Within this family, the
presence of multiple HNPGLs was common, and no cases of meta-
static disease were found.65
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4 | CONSEQUENCES OF SDH DEFICIENCY
OR LOSS
In SDHx germline mutation carriers affected by a second hit, SDH loss
of function leads to the accumulation of succinate in the tumor
cells,68-72 which is the hallmark of tumorigenesis of these tumors This
accumulation inhibits several α-ketoglutarate dioxygenases, which are
involved in the induction of the pseudohypoxia pathway and in epige-
netic DNA modifications. Moreover, SDH deficiency or loss may lead
to overproduction of reactive oxygen species (ROS) and to a
“rewiring” of the cell's metabolism.
4.1 | Accumulation of succinate induces the
pseudohypoxia pathway
Tumors harboring a SDHx mutation have a strong hypoxic signature.
PGL/PCCs have historically been closely associated with hypoxia,
because these highly vascularized tumors arise either in tissues known to
be susceptible to low oxygen levels (adrenal medulla, organ of
Zuckerkandl), or in cells known to serve as oxygen sensors (carotid body).
The major regulator of hypoxia response is the transcription factor
HIF. HIF activity is regulated by TCA cycle metabolites. HIF is a
heterodimer and consists of two subunits, one α subunit and one β sub-
unit. There are three different α-subunits: HIF1α, HIF2α and HIF3α, and
two different β subunits: HIF1ß (aryl hydrocarbon receptor nuclear
translocator [ARNT1]) and ARNT2. Whereas the β subunits are constitu-
tively expressed, the active α subunits HIF1α and HIF2α are degraded in
the presence of oxygen and therefore function as gatekeepers in
response to low oxygen. Under normoxic conditions, HIFα is continuously
synthesized, and propyl hydroxylase domain (PHD) marks it for degrada-
tion, involving the activity of the VHL ubiquitination complex (pVHL). The
hydroxylation reaction performed by the PHD enzymes requires oxygen
and α-ketoglutarate as substrates, as well as iron and ascorbate as cofac-
tors.73 Thus, during hypoxia PHD becomes inactive, and as a result HIFα
escapes pVHL recognition and degradation. The unmodified HIFα mole-
cule translocates to the nucleus, where it forms a transcriptionally active
HIFα heterodimer with a stable HIFβ subunit. This active transcription
factor induces a wide variety of target genes involved in cellular adapta-
tion to hypoxia as in angiogenesis, energy metabolism, and cell survival.
In a SDH deficient condition, the excess of accumulated succinate is
shuttled from the mitochondrial matrix to the cytoplasm, where it com-
petes with α-ketoglutarate in binding to PHD and inhibiting PHD. This
consequently leads to the stabilization of HIFα even in the presence of
oxygen, a condition known as pseudohypoxia.3,68,74-76
HIFα regulates the transcription of several genes known to be
involved in tumorigenesis, angiogenesis, extracellular matrix elements
and energy metabolism. HIF1α and HIF2α share the target genes vas-
cular endothelial growth factor (VEGF), glucose transporters 1 and
3 (GLUT1 and GLUT3) and hexokinase 2. HIF1α stimulates the
expression of various glycolytic enzymes and HIF2α stimulates the
expression of platelet-derived growth factor (PDGF) and erythropoie-
tin (EPO).9 Pollard et al showed the overexpression of HIF1α in SDHx
tumors compared to tumors with other germline mutations,71,77 while
others studies showed overexpression of HIF2α in SDHx related
tumors compared to sporadic PGL/PCC.78-80 The role of HIF3α in
relation to tumorigenesis remains to be elucidated, although, previous
studies have indicated that HIF3α may suppress the expression of
genes induced by HIF1α and HIF2α (for review see Reference 81).
Heat shock proteins (HSPs) are molecular chaperones that are
important for protein assembly, folding and stability and play a central
role in cell proliferation, survival and tumor progression. HSP90 is
involved in the stability of HIF1α.9 HSP90 has been shown to be over-
expressed in metastatic PGL/PCC compared with benign PGL/PCC.82
Inhibition of HSP90 leads to downregulation of HIF1α and is a poten-
tial target for therapy in metastatic PGL/PCC.83
4.2 | Accumulation of succinate leads to a
hypermethylator phenotype
Recent studies have observed a hypermethylator phenotype in SDH
deficient PGL/PCC.84-86 Next to PHD, accumulation of succinate
competitively inhibits other α-ketoglutarate-dependent dioxygenases,
including jumonji-domain histone demethylases (JmjC) and the ten-
eleven translocation (TET) family of DNA methylase (Figure 2). Inhibi-
tion of these dioxygenases leads to hypermethylation of promotor
regions (CpG islands) of several genes (also known as CpG island
methylator phenotype [CIMP]). Because methylation triggers gene
transcription deregulation, hypermethylation of tumor-suppressor
gene promotors plays an important role in tumorigenesis.
Letouzé et al determined the DNA methylation profiles of a large
PGL/PCC cohort. They identified 191 genes showing significant
hypermethylation, due to an inhibition of DNA demethylation, and
downregulation in SDHx-related PGL/PCC.84 The most significant epi-
genetically silenced genes were those encoding phenyl-ethanolamine-
N-methyltransferase (PNMT) and keratine 19 (KRT19), which are
involved in neuroendocrine differentiation and in epithelial-to-
mesenchymal transition (EMT).84
PNMT catalyzes the conversion of norepinephrine to epinephrine.
Next to the PNMT gene, four other genes that we found to be hyper-
methylated, are involved in the catecholamine secretion: SULT1A1,
DRD2, NPY, and SLC6A2.84 Reduced expression of these genes leads
to an immature catecholamine secretory profile with predominant
excretion of norepinephrine and dopamine. In SDHB mutated tumors
the level of hypermethylation seems to be significantly higher com-
pared to other SDHx mutated tumors, and the expression of these tar-
get genes significantly lower. The authors hypothesize that SDH
inactivation may be more complete in SDHB mutated tumors com-
pared to tumors harboring a mutation in the other subunits, leading to
a higher succinate accumulation and hence a stronger inhibition of
α-ketoglutarate-dependent demethylation.84 This could be an expla-
nation for the higher metastatic risk in SDHB-related tumors.
The study of Richter et al confirmed that tumor succinate:fuma-
rate ratios were higher in tumors of patients with SDHB mutations
compared to tumors of patients with an SDHC/D mutation.87 EMT is a
process by which epithelial cells lose their polarity and cell-to-cell
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adhesion, thereby gaining migratory and invasive properties to
become mesenchymal stem cells. This process, normally occurring
during embryonic development, can be reactivated in cancer cells
and is involved in metastatic dispersion.88 Several genes and signal-
ing pathways have been identified as involved in different parts of
the induction of EMT. KRT19 encodes an intermediate filament
required for the formation of desmosomes (structure specialized for
cell-to-cell adhesion) and shown to be downregulated in SDHB met-
astatic PGL tissue samples unlike non-SDHB metastatic PGL tissue
samples.89 EMT is the first pathway identified that may be responsi-
ble for the specific metastatic properties of SDHB-related PGL
and PCC.
Kiss et al showed that the tumor suppressor gene P16 was hyper-
methylated in SDHB mutated tumor tissue samples as opposed to
RET-, VHL- or NF-related PGL/PCC.90 P16 is an inhibitor of cyclin-
dependent kinases and plays an important role in cell cycle regulation
by decelerating the cells progression from G1 phase to S phase, and
acts therefore as a tumor suppressor. The authors showed that
hypermethylation of P16 was associated with short disease-related
survival.90
4.3 | SDH loss leads to overproduction of reactive
oxygen species
Reactive oxygen species (ROS) are damaging molecules containing
oxygen with an unpaired free electron, such as superoxide and
hydrogen peroxide. Although ROS are critical for normal cell func-
tion, they also lead to oxidative damage of DNA, which leading to
genomic instability and finally to apoptosis. Mitochondria are the
major source of ROS, especially complexes I and III, although
F IGURE 2 Consequences of succinate dehydrogenase (SDH) loss. SDH loss leads to the accumulation of succinate which inhibits a-
ketoglutarate dependent dioxygenases including prolyl-hydroxylases (PHD), ten–eleven translocation (TET) and jumonji C-domain-containing
proteins (JmjC)
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complex II can also produce a significant number.91,92 Accumula-
tion of succinate results in an over-reduced ubiquinone pool
resulting in a reverse electron transfer to complex I, where elec-
trons escape as ROS.93 Excessive ROS levels have been shown to
stabilize HIFα and induce the pseudohypoxia pathway in SDHx-
mutated PGL/PCC.94 In addition to the stabilization of HIFα,
SDHx-mutation-induced increases in ROS have been shown to
cause genomic instability that may contribute to tumorigene-
sis.95,96 Nevertheless, experimental evidence for ROS in various
models of SDH dysfunction is not consistent, as some suggests
that ROS are increased or normal, a finding which is extensively
reviewed by Kluckova and coworkers.8
4.4 | SDH loss leads to changes in the cell's
metabolism pathways
SDH deficiency or loss can lead to reprogramming of cancer-related
cell metabolism such as enhanced glycolysis (Warburg effect), as well
as changes in anaplerotic pathways and in oxidative phosphorylation
(Figure 3).
4.4.1 | Warburg effect
As stated above, SDHx-related tumors display the Warburg effect.
The main driver of the Warburg effect is HIFα which induces
expression of GLUT1 and GLUT3, hexokinase 2, pyruvate kinase
variant M2 (PKM2) and lactate dehydrogenase A (LDH-A),
thereby enhancing the glycolytic pathway.97 PKM2 interacts with
HIF1α in the nucleus, where it functions as a coactivator to
increase the expression of HIF1α target genes that stimulate the
shift from oxidative phosphorylation to glycolysis.98,99 Favier
et al and Fliedner et al found an overexpression of LDH-A in
SDHx-related tumors.100,101 LDH-A converts pyruvate to lactate,
thereby recovering the NAD+ needed to maintain glycolysis, criti-
cal for tumor proliferation in vivo.100 The generated lactate leads
to an acid tumor microenvironment, which in turn may facilitate
F IGURE 3 Metabolic pathways in which succinate dehydrogenase (SDH) loss is involved, including glycolysis, tricarboxylic acid cycle and
anaplerotic reactions. The first step in glycolysis is the phosphorylation of glucose to glucose-6-phosphate by hexokinase1. Lactate
dehydrogenase A (LDH-A)2 catalyzes the conversion of pyruvate and lactate with concomitant conversion of nicotinamide adenine dinucleotide
(NADH) and NAD+. Pyruvate carboxylase3 catalyzes the conversion of pyruvate to oxaloacetate. Proposed metabolic changes in SDH loss are
enhanced glycolysis, via activation of LDH-A and hexokinase. Furthermore, pyruvate carboxylase may be upregulated in SDH loss and there may
be an increased glutamine metabolism. A more detailed explanation is described in the text
EIJKELENKAMP ET AL. 45
tumor invasion and migration and is correlated with a poor
prognosis.102
4.4.2 | Anaplerotic pathways
Pyruvate carboxylase, catalyzing pyruvate to oxaloacetate, an impor-
tant anaplerotic reaction, may be upregulated in SDHx tumors. Cardaci
et al showed that pyruvate carboxylase is upregulated in SDHB null
cells. Silencing of the pyruvate carboxylase gene both significantly
reduced the proliferation of SDH cells in vitro and delayed the onset
of tumor in vivo, compared to SDH proficient cells/mice. By identify-
ing pyruvate carboxylase as an essential gene for SDH-deficient cells
but dispensable for normal cells, this study unveils a metabolic vulner-
ability for potential treatment of SDHx-associated tumors.103
Lussey-Lepoutre et al showed that in SDHx-mutated tumor cells
the increased synthesis of oxaloacetate is essential in order to pro-
duce aspartate (as well as to continue a truncated oxidative TCA
cycle). Aspartate is an important precursor for protein and nucleotide
biosynthesis for anabolic purposes. In SDH deficient cells, as com-
pared to wild type cells, knockdown of pyruvate carboxylase results in
complete ablation of proliferation. The authors also showed the use
of glutamine and glutamate to provide intermediates that are lacking
due to TCA disturbance.104 Tannahill et al and Imperiale et al also
showed an increased import and metabolism of glutamine in SDHx-
related tumors.105,106
4.4.3 | Oxidative phosphorylation
Disruption of complex II leads to changes in the TCA cycle, but also to
changes in oxidative phosphorylation in the form of upregulation of
complex I. Pang et al showed that in tumor tissue and in an SDHB-
knockdown mouse cell line, complex I components and activity are
upregulated.107 Consequently, the quantity of NAD+ in tumor tissue
was 2.7-fold higher in cluster I than in cluster II tumors. NAD+ is a
cofactor that supports the poly (ADP-ribose) polymerase (PARP) DNA
repair way. PARP is an enzyme which produces ADP-ribose-
conjugated PARP, involved in repair and stabilization of DNA. As an
enhanced NAD+/PARP pathway was linked to chemoresistance in
SDHB mutation carriers,107 inhibition of PARP could be a potential
target to support chemotherapy, as further explained below.
5 | APPLICATIONS FOR DIAGNOSTICS OF
PGL/PCC
5.1 | SDH and immunohistochemistry
In the vast majority of SDHx-associated tumors, loss of SDHB protein
expression can be detected by immunohistochemical staining with a
high sensitivity and specificity (100% and 84%, respectively).33,108
SDHB immunohistochemistry can therefore discriminate between
SDHx-related and non-SDHx-related PGL/PCC. Loss of both SDHB
and SDHA immunoreactivity is shown only in the context of a SDHA
mutation.3,23,33,61,108 SDHB and/or SDHA immunohistochemical
expression could precedegenetic testing,33 or be used to classify vari-
ants of unknown significance.
The presence of an SDHB mutation is a predictor of metastasis in
PGL/PCC. The current definition of a metastatic PGL or PCC
according to the World Health Organization includes the presence of
metastasis in non-chromaffin tissue.2 In spite of attempts to develop
an effective system for predicting the metastatic potential of
PGL/PCC, none has yet resulted in a reliable classification. Recently, a
grading system for PCC and PGL (GAPP) was developed.109 This score
combines pathological features with biochemical phenotypes but does
not include the SDHB mutational status of the tumor. Therefore, a
combination of the GAPP and SDHB immunohistochemistry (modi-
fied-GAPP or M-GAPP) has been suggested as a valuable tool for
predicting metastatic disease.109 Koh et al validated the M-GAPP
score in a retrospective cohort of 72 PGL/PCC patients with a mean
follow-up of 44 months. The M-GAPP score was significantly higher
in the 12 patients who developed metastatic disease.110
5.2 | Metabolomics: measuring succinate levels in
plasma, urine and tumor tissue
Succinate can be measured in plasma, urine and tumor tissue. Hobert
et al measured succinate concentrations using gas chromatography-
mass spectrometry in plasma and urine of patients with germline
SDHB, SDHD, PTEN mutations and patients with sporadic PGL/PCC.
In three out of six SDHx mutation carriers (without PGL) elevated
plasma succinate was recorded, while it was not elevated in any of
patients with sporadic PGL/PCC.111
Tumor tissue can be used to measure the succinate:fumarate ratio
using liquid chromatography-mass spectrometry (LC-MS).112,113 An
elevated succinate:fumarate ratio provides a diagnostic sensitivity of
93% and sensitivity of 97% to identify SDHx mutated PGL/PCC.87
Richter et al used 50 frozen specimens from 49 patients as a training
set and 184 tumor samples as a validation set. In their study, succi-
nate:fumarate ratios were higher in SDHB-related PGL/PCC compared
to SDHC/D tumors,87 thereby supporting Letouzé's suggestions84 that
in a more complete inactivation of the SDH protein is present in
SDHB-mutation carriers. Measuring the succinate:fumarate ratio in
tumor tissue can help to identify the underlying germline or somatic
pathogenic mutation, especially when genetic mutation is inconclu-
sive. Whether it may also have a prognostic value to predict meta-
static disease still needs to be determined.
The studies of Lendvai et al and Imperiale et al confirm the find-
ings that succinate:fumarate ratios are higher in SDHB- and SDHD-
related PGL/PCC than in apparently sporadic and non-SDHx-mutated
PGL/PCC (n = 8).72,106 Imperiale et al also found significantly lower
levels of glutamate in SDHx-related tumors.106 In an additional study,
Richter et al, used LC-MS to screen 395 PGL/PCC tissues for TCA
cycle metabolites to indicate TCA cycle aberrations. SDHx-mutated
tumors were characterized by high succinate levels and low levels of
all other TCA cycle metabolites including glutamate and aspartate.112
High resolution magic angle spinning (HR-MAS) nuclear magnetic
resonance (NMR) spectroscopy is a new technique that can be used to
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analyze catecholamine and succinate levels both in vivo and ex vivo.
The HR-MAS NMR technique was used by the group of Taïeb to
investigate the metabolic profile of SDHx-mutated tumor tissue and
to compare this profile to the metabolic profile of apparently spo-
radic and VHL tumor tissue.114 SDHx-related tumors had increased
levels of succinate and significantly decreased levels of glutamate
compared to apparently sporadic tumors and VHL-related tumors.106
The same group also explored the possibility of quantification of
oncometabolites in tissue when the tumor is still inside the patient,
and shown in eight patients that 1H-MRS (1high magnetic resonance
spectroscopy) adequately detected succinate resonance peaks in
four patients with an SDHx-related tumor.115 In addition, Lussey-
Lepoutre et al used 1H-MRS to detect succinate levels in both mice
and patients with PGL in vivo. Five patients had a SDHx gene muta-
tion and in these patients a succinate peak could be detected.116
This offers unique opportunities for better characterizing these
tumors at a metabolic level.
5.3 | Altered cell metabolism pathways: The use of
18F-fluorodeoxyglucose positron emission tomography
According to Endocrine Society PGL/PCC guidelines, 18F-fluorode-
oxyglucose (FDG) positron emission tomography (PET)/computed
tomography (CT) is the preferred imaging modality in SDHB-mutated
PGL/PCC.117 Recent studies have shown that SDHx-related PGL/PCC
might be better visualized by [68Ga]-DOTA(0)-Tyr(3)-octreotate
([67GA]-DOTATATE) PET/CT than 18F-FDG PET/CT, especially those
located in the head and neck region as well as metastatic
PGL/PCC.118-120 The sensitivity of FDG-PET for SDHx related tumors
varies between 83% and 100%.118,121-123
Like glucose, 18F-FDG is taken up by tumor cells mostly via GLUT.
After cell entry, 18F-FDG is phosphorylated by hexokinase into 18F-FDG-
6-P, which, unlike glucose-6-P, cannot be further metabolized along the
glycolytic pathway. Because the cell membrane is impermeable to 18F-
FDG-6-P, it accumulates within cells in a manner directly proportionate
to their metabolic activity. An increased glucose uptake and consumption
due to an increase in glycolysis leads to a high uptake of 18F-FDG.124
18F-FDG uptake in any cell is determined by expression of GLUTs and
activity of hexokinase. Van Berkel et al studied the expression of GLUT
and hexokinase in 27 tumor tissues from patients with hereditary tumors,
using immunohistochemical staining and analyzed preoperative 18F-FDG
PET scans. The expression of hexokinase-2 and hexokinase-3 was signifi-
cantly higher in SDHx-mutated PGL/PCC than in sporadic tumors, and
the mean standardized uptake values of the 18F-FDG PET scans corre-
lated with the expression of hexokinase-2 and -3.124
Increased levels of succinate may also play a role in the high
uptake of 18F-FDG by SHDx-related tumors. Garrigue et al showed
that intratumoral injection of succinate significantly increased 18F-
FDG uptake in vivo and in vitro.125 Moreover, laser-doppler did not
show succinate induced 18F-FDG uptake to be because of increased
blood flow or increased capillary permeability.125
6 | IMPLICATIONS FOR TREATMENT OF
METASTATIC PGL/PCC
The cornerstone treatment for patients with benign SDHx related
PGL/PCC is surgery.117 As described above, SDHB-mutation carriers
are those especially at risk of metastatic disease. Even for patients
with metastatic PGL/PCC, resection of the primary tumor seems to
be associated with a better overall survival.126 Metastases frequently
occur in lymph nodes (distant and regional), bones, liver and lungs.
Until now, there is no curative therapy for patients with metastatic
disease. The main focus of treatment is on controlling the secretion of
catecholamines, thereby alleviating symptoms and controlling tumor-
related complaints. Systemic treatment options include radionuclide
therapy using 131I Metaiodobenzylguanidine (MIBG), peptide receptor
radionuclide therapy (PRRT) and chemotherapy. As described above,
insight in the pathways leading to tumor formation and potential met-
astatic disease in patients with SDHx mutations, may lead to a better
response to existing therapies and provide us with a unique opportu-
nity to develop novel targeted therapies.
6.1 | Targeting the pseudohypoxia pathway
6.1.1 | Restoration of PHD activity
Succinate competes with α-ketoglutarate in binding to PHD, thereby
inhibiting PHD activity; therefore excess of α-ketoglutarate could
restore PHD.11,127-129 Increasing levels of intracellular α-ketoglutarate
have been shown to affect the levels of HIF1α in vitro.127 As succi-
nate and hypoxia act synergistically in inhibiting PHD activity, not only
administering α-ketoglutarate but also inducing hyperoxia might
restore PHD activity.130,131 Increasing the α-ketoglutarate levels in
the cell, is challenging. In a recent mouse model study of breast can-
cer, the α-ketoglutarate dehydrogenase (KGDH) inhibitor (AA6) was
able to cause intracellular α-ketoglutarate accumulation.132
6.1.2 | HIF2α inhibition
In the HIF2α structure is a specific cavity which can be
targeted.133,134 Two compounds, PT2385 and PT2399, have been
developed to serve as an HIF2α inhibitor. Both compounds, studied
in vitro and in vivo, efficiently reduced the growth of clear cell
RCCs.135,136 A recent publication describes a phase I trial with
PT2385 in patients with progressive clear cell RCCs. All 25 patients
included in the expansion phase had locally advanced disease or dis-
ease that had progressed during a median of four prior regimens.
Respectively, 2%, 12%, and 52% of patients had complete response,
partial response and stable disease, results which are very promis-
ing.137 Although at present no intervention studies are being under-
taken in patients with metastatic SDHx- related PGL/PCC, probably in
the near future a phase II trial will start to evaluate HIF2α inhibitors
for patients with metastatic PGL/PCC.133,138
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6.1.3 | Tyrosine kinase inhibitors
Treatment with Tyrosine Kinase Inhibitors (TKI) targets the down-
stream pathway of HIF. Several TKI's that been described in case
reports, series or phase II trials, such as sunitinib, cabozantinib,
lenvatinib, pazopanib, and axitinib. An excellent overview of existing
data and forthcoming trials was recently published by Toledo and
Jiminez.139 All TKIs inhibit angiogenesis, by inhibiting the activation of
the VEGF receptor (VEGFR).
Until now, most available data are for sunitinib. Besides inhibiting
the activation of the VEGFR, sunitinib also inhibits the activation of
the PDGF receptor and the receptor of RET, c-KIT and Fms-like tyro-
sine kinase (FLT). Canu et al reviewed the efficacy of sunitinib in
35 patients, of whom 13 were carriers of an SDHB germline mutation.
Outcome did not differ between patients with or without an SDHB
mutation.140 In a retrospective analysis of 17 patients with progres-
sive disease, who received sunitinib, 47% had a partial response or
stable disease. Positive responses were noted in carriers of SDHB
mutations as well as in patients with apparently sporadic tumors.
Progression-free survival was only 4.1 months.141 Currently two
phase II studies are being conducted; the Study Of Sunitinib In
Patients With Recurrent Paraganglioma/Pheochromocytoma SNIPP
(closed) and the First International Randomized Study in Malignant
Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPP).
Pazopanib, similar to sunitinib, also inhibits the action of VEGFR,
PDGFR and the RET receptor, but additionally inhibits the fibroblast
growth factor receptor (FGFR). Pazopanib was studied in a phase II trial,
terminated due to poor accrual after including only seven patients.142
Six patients were evaluated, as one withdrew informed consent. Of the
six only one patient had a partial response, lasting 2.4 years.
Preliminary results of axitinib were presented at the ASCO meet-
ing in 2015. Axitinib only blocks VEGFR, and led to a partial response
in three out of nine patients with metastatic PGL/PCC; moreover tox-
icity led to a high rate of dose reduction.143
Cabozantinib seems a promising TKI for patients with metastatic
PGL/PCC, especially for patients with bone metastases. Cabozantinib
also inhibits the c-Met receptor pathways and may therefore delay
the development of resistance, as this pathway is upregulated by
VEGFR inhibition. Currently there is a phase II trial ongoing, with
promising preliminary results.144
Another phase II trial is aiming to evaluate the response rate of
lenvatinib in a group of 25 patients with metastatic PGL/PCC.
Lenvatinib, like pazopanib, also inhibits FGFR.
6.1.4 | Heat shock protein 90 inhibitors
Inhibition of HSP90 leads to downregulation of HIF1α and is a poten-
tial target for therapy in metastatic PGL/PCC. Giubellino et al showed
potent inhibition of proliferation in PCC cell lines by tanespimycin
(17-AAG) and ganetespib. Furthermore, they showed the efficacy of
17-AAG and ganetespib in reducing metastatic burden and increasing
survival in a metastatic model of PCC.83 Chae et al suggested that
HSP90 could be especially effective in SDHB-mutated tumors.
Genetic inactivation of SDHB leads to a recruitment of HSP90 to the
mitochondria, to help compensate for the impaired oxidative phos-
phorylation. As HSP90 promotes the stability of HIFα, its inhibition
can lead to the death of these cells.145
6.2 | Targeting the hypermethylator phenotype of
SDHx related PGL/PCC
Chemotherapy is, in contrast to therapies mentioned above, widely
available for the treatment of metastatic PGL/PCC. The combination
of cyclophosphamide, vincristine and dacarbazine (CVD) is the most
studied and is currently first line chemotherapy in patients with a met-
astatic PGL/PCC. However, in the absence of prospective studies, the
evidence is only based on small retrospective studies.141,146-151 In
2014, a meta-analysis was performed suggesting a partial response of
37%.152
Some reports however, suggest a higher response rate to
temozolomide, an oral alternative to dacarbazine, in patients with
SDHB mutations. Temozolomide is a DNA alkylating agent, leading to
methylation of the O6-position of guanine, resulting in DNA adduc-
tion. These DNA adducts result in apoptosis of the malignant cell. The
O(6)-methylguanine-DNA-methyltransferase (MGMT) enzyme is
capable of repairing the DNA adducts. Therefore, the efficacy of
treatment with temozolomide is associated with the expression of
MGMT in the tumor cells. In a study by Hadoux et al, 11 out of
14 patients with progressive metastatic disease, had a SDHB muta-
tion.153 Thirty-six percent had partial response, 55% stable disease
and 9% progressive disease. The authors observed a longer
progression-free survival in patients with an SDHB mutation com-
pared to patients without an SDHB mutation (19.7 vs 2.9 months).
The higher response rate in patients with SDHB mutations could be
caused by hypermethylation of the MGMT promotor region and con-
sequently lower MGMT expression.
Recently two patients with a SDHB metastatic PGL/PCC showed
a clinical benefit from temozolomide even after disease progression
on CVD. Both patients showed hypermethylation of the MGMT pro-
motor region, suggesting that monotherapy of temozolomide may
benefit patients with metastatic SDHB-related PGL/PCC.154 Very
recently Jawed et al studied 12 patients with a metastatic PGL/PCC,
all with SDHB mutation, who received CVD; a marked efficacy was
noted.155 Two out of 12 patients had a complete remission and eight
patients a partial response. The median duration of response was
478 days, with a median progression-free survival of 930 days.
Decitabine, registered for the treatment of acute myeloid leuke-
mia, is a cytidine deoxynucleoside-analog. It inhibits DNA-
methyltransferase and therefore acts as a hypomethylating agent. In
two cell models decitabine was able to induce cell death of SDH −/−
cells.84,156
6.3 | Preventing ROS damage
Ascorbic acid, α-tocopherol (vitamin E) and N-acetylcysteine all act as
antioxidants preventing ROS damage, thereby diminishing
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tumorigenesis primarily through decreasing DNA damage and muta-
tions. There is, however, limited evidence for this efficacy in SDHx
mutated PGL/PCC.157,158
6.4 | Targeting the altered cell's metabolism
6.4.1 | Inhibiting glycolysis
As discussed above, SDHx-related PGL/PCC are “glucose addicts.”
Interventions aiming to inhibit glycolysis could therefore be an inter-
esting and several potential options exists. WZB117 and STF-31 are
inhibitors of GLUT1, downregulating glycolysis and inhibiting cancer
cell growth in vitro and vivo.159 Dichloroacetate (DCA) downregulates
pyruvate dehydrogenase kinase. (Normally this upregulates pyruvate
dehydrogenase involved in the glycolysis). This shifts glycolysis to oxi-
dative phosphorylation and induces apoptosis in cancer cells. Pyruvate
carboxylase was identified as an essential gene for SDH-deficient cells
(although dispensable for normal cells), a metabolic vulnerability offer-
ing a potential target for treatment of SDHx-associated tumors.103
6.4.2 | Inhibiting the effects of upregulation of
complex I
As noted above another way to become resistant to chemotherapy is
via the NAD+/PARP-pathway. In the study of Pang et al the combina-
tion of temozolomide with a PARP inhibitor led to increased mouse
survival in a metastatic PGL/PCC allograft model (52 days compared
with 42 days).107 Notably, one of the postulated pathways through
which metformin exerts an anti-tumor effect is also through inhibition
of complex I, implying that metformin could also act as a potential
chemosensitizer in patients with SDHx-related metastatic PGL/PCC.
7 | CONCLUSION
Recent years, we have seen an increase in knowledge regarding the
consequence of loss of the SDH enzyme in the pathogenesis of (meta-
static) PGL/PCC in patients harboring an SDHx mutation. The accumu-
lation of succinate and the impairment of the complex II function of
oxidative phosphorylation leads, via the pseudohypoxic pathway,
induction of ROS, and rewiring of the cell's metabolism to tumor for-
mation. The advantages of new insight into these pathophysiological
characteristics provide new directions for diagnostics and therapeutic
options in metastatic SDHx-related PGL and PCC.
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